Hikma Pharmaceuticals appoints Sigurdur Olafsson as CEO
Mr Olafsson will also join Hikma's Board of Directors as an executive director, subject to election at the next annual general meeting in May 2018.
Mr. Olafsson has significant international experience in the pharmaceutical industry.
He was most recently President and Chief Executive Officer of the Global Generic Medicines Group of Teva Pharmaceuticals, a position he held from 2014 to 2016.
From 2012 to 2014, he was President of Actavis.
Prior to this, he was Executive Vice President, Global Generics, at Actavis plc (Watson) from 2010 to 2012; and CEO of the Actavis Group from 2008 to 2010.
From 2003 to 2008, he held positions of increasing responsibility within the Actavis Group, including Deputy CEO, Vice President of Corporate Development and CEO of Actavis Inc. US.
From 1998 to 2003, he held positions of increasing responsibility with Pfizer's Global R&D organization in the UK and US.
From 1994 to 1998, he served as Head of Drug Development for Omega Farma in Iceland.
Mr. Olafsson currently serves as a member of the board of directors for Elucida Oncology and Pfenex Inc.